Skip to main content

Table 1 Demographic and baseline clinical characteristics of the study sample (n = 3685)

From: Effective public-private partnerships for sustainable antiretroviral therapy: outcomes of the Right to Care health services GP down-referral program

 GP down-referredClinic A controlsClinic B controlsTotal
373 (10.1)2599 (70.5)713 (19.4)3685 (100.0)
n (%)n (%)n (%)n (%)
Sex
 Female258 (69.2)1717 (66.1)463 (64.9)2438 (66.2)
 Male115 (30.8)882 (33.9)250 (35.1)1247 (33.8)
Age at down-referral/eligibility (years) Median (IQR)40.6 (35.9–47.2)38.9 (33.8–44.9)39.7 (33.3–47.4)39.3 (33.9–45.7)
 18–29.9921 (5.6)301 (11.6)109 (15.3)431 (11.7)
 30–39.99150 (40.2)1117 (43.0)251 (35.2)1518 (41.2)
 40–49.99133 (35.7)855 (32.9)224 (31.4)1212 (32.9)
 50+69 (18.5)326 (12.5)129 (18.1)524 (14.2)
Nationality
 South African316 (84.7)2281 (87.8)696 (97.6)3293 (89.4)
 Non-South African57 (15.3)318 (12.2)17 (2.4)392 (10.6)
Education level
 Primary school or less58 (15.5)386 (14.9)216 (30.3)660 (17.9)
 Some secondary school105 (28.2)685 (26.4)28 (3.9)818 (22.2)
  > =Grade 12180 (48.3)1107 (42.6)433 (60.7)1720 (46.7)
 Missing30 (8.0)421 (16.2)36 (5.0)487 (13.2)
Employment status
 Employed238 (63.8)1430 (55.0)209 (29.3)1877 (50.9)
 Unemployed130 (34.9)1125 (43.3)472 (66.2)1727 (46.9)
 Missing5 (1.3)44 (1.7)32 (4.5)81 (2.2)
Time on ART at down-referral/eligibility (years) Median (IQR)4.2 (2.7–6.3)3.0 (1.9–5.0)2.1 (1.5–3.7)3.0 (1.8–4.9)
 1–2.9 year104 (27.9)1281 (49.3)480 (67.3)1865 (50.6)
 3–4.9 years111 (29.8)678 (26.1)136 (19.1)925 (25.1)
 > = 5 years158 (42.4)640 (24.6)97 (13.6)895 (24.3)
Guideline year of ART initiation
 2004–2010205 (55.0)1828 (70.3)361 (50.6)2394 (65.0)
 2011–2014168 (45.0)771 (29.7)352 (49.4)1291 (35.0)
Baseline CD4 (cells/μl)
 250–349.9152 (40.8)679 (26.1)196 (27.5)1027 (27.9)
 350–499.9137 (36.7)854 (32.9)228 (32.0)1219 (33.1)
  > =50084 (22.5)1066 (41.0)289 (40.5)1439 (39.1)
Baseline VL (copies/ml)
  < 50297 (79.6)1466 (56.4)475 (66.7)2238 (60.8)
 50–19961 (16.4)698 (26.9)151 (21.2)910 (24.7)
 200–39915 (4.0)434 (16.7)86 (12.1)535 (14.5)
Baseline Haemoglobin (g/dL) Med (IQR)14.0 (13.0–14.8)13.9 (12.9–15.0)14.0 (13.0–14.9)13.9 (12.9–14.9)
Baseline BMI (kg/m2)
 Normal241 (64.6)993 (38.2)291 (40.8)1525 (41.4)
 Overweight82 (22.0)593 (22.8)158 (22.2)833 (22.6)
 Obese46 (12.3)350 (13.5)101 (14.2)497 (13.5)
 Missing4 (1.1)663 (25.5)163 (22.9)830 (22.5)
ART regimen
 TDF + 3TC/FTC + EFV/NVP172 (46.1)754 (29.4)342 (48.0)1268 (34.8)
 AZT + 3TC + EFV/NVP18 (4.8)152 (5.9)24 (3.4)194 (5.3)
 d4T + 3TC + EFV/NVP183 (49.1)1656 (64.6)347 (48.7)2186 (59.9)
Comorbidities in the 12 month follow-up
 No366 (98.1)2529 (97.3)694 (97.3)3589 (97.4)
 Yes7 (1.9)70 (2.7)19 (2.7)96 (2.6)
12 month Retention
 Alive and in care331 (88.7)1736 (66.8)367 (51.5)2434 (66.1)
 LTFU42 (11.3)83 (3.2)175 (24.5)300 (8.1)
 Deceased026 (1.0)7 (1.0)33 (0.9)
 Transferred out0754 (29.0)164 (23.0)918 (24.9)
12 month-VL suppression (< 50 copies/mL)
 Unsuppressed119 (31.9)967 (37.2)260 (36.5)1346 (36.5)
 Suppressed228 (61.1)934 (35.9)373 (52.3)1535 (41.7)
 Missing26 (7.0)698 (26.9)80 (11.2)804 (21.8)
  1. IQR, interquartile range; ART, antiretroviral therapy; VL, viral load; BMI, body mass index; 3TC, Lamivudine; EFV, efavirenz; TDF, tenofovir; NVP, Nevirapine; AZT, Zidovudine; FTC, emtricitabine; d4T, stavudine